First-in-human assessment of the novel PDE2A PET Radiotracer 18F-PF-05270430

Journal of Nuclear Medicine

Volumn 57, Issue 9, 2016, Pages 1388-1395

  Naganawa, Mika ^a   Waterhouse, Rikki N ^b   Nabulsi, Nabeel ^a   Lin, Shu Fei ^a   Labaree, David ^a   Ropchan, Jim ^a   Tarabar, Sanela ^b   Demartinis, Nicholas ^b   Ogden, Adam ^b   Banerjee, Anindita ^b   Huang, Yiyun ^a   Carson, Richard E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

Brain imaging; Dosimetry; Phosphodiesterase 2A; Positron emission tomography; Test retest reproducibility

Indexed keywords

PF 05270430 F 18; PHOSPHODIESTERASE; PHOSPHODIESTERASE 2A; TRACER; UNCLASSIFIED DRUG; 4-(3-FLUOROAZETIDIN-1-YL)-7-METHYL-5-(1-METHYL-5-(4-(TRIFLUOROMETHYL)PHENYL)-1H-PYRAZOL-4-YL)IMIDAZO(5,1-F)(1,2,4)TRIAZINE; AZABICYCLO DERIVATIVE; AZETIDINE DERIVATIVE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 2; PDE2A PROTEIN, HUMAN; RADIOPHARMACEUTICAL AGENT;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOSIMETRY; FEMALE; HEART RATE; HEMATOCRIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IMMUNOREACTIVITY; LIPOPHILICITY; MALE; NONHUMAN; NORMAL HUMAN; OXYGEN SATURATION; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOCHEMISTRY; REPRODUCIBILITY; TEST RETEST RELIABILITY; TISSUE DISTRIBUTION; ANIMAL; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; BLOOD; BRAIN; COMPUTER SIMULATION; DIAGNOSTIC IMAGING; FEASIBILITY STUDY; ISOTOPE LABELING; METABOLIC CLEARANCE RATE; METABOLISM; MOLECULAR IMAGING; PILOT STUDY; PROCEDURES; RHESUS MONKEY; SENSITIVITY AND SPECIFICITY;

ANIMALS; AZABICYCLO COMPOUNDS; AZETIDINES; BRAIN; COMPUTER SIMULATION; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; FEASIBILITY STUDIES; FEMALE; HUMANS; ISOTOPE LABELING; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MOLECULAR IMAGING; ORGAN SPECIFICITY; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84989291187     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.166850     Document Type: Article

References (19)

1. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481-511.
2. Pandit J, Forman MD, Fennell KF, Dillman KS, Menniti FS. Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the x-ray structure of a near full-length construct. Proc Natl Acad Sci USA. 2009;106:18225-18230.
3. Stephenson DT, Coskran TM, Kelly MP, et al. The distribution of phosphodiesterase 2A in the rat brain. Neuroscience. 2012;226:145-155.
4. Stephenson DT, Coskran TM, Wilhelms MB, et al. Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. J Histochem Cytochem. 2009;57:933-949.
5. Zhang L, Villalobos A, Beck EM, et al. Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand. J Med Chem. 2013;56:4568-4579.
6. Chen L, Nabulsi N, Naganawa M, et al. Preclinical evaluation of 18F-PF- 05270430, a novel PET radioligand for the phosphodiesterase 2A enzyme. J Nucl Med. May 19, 2016 [Epub ahead of print].
7. Cristy M, Eckerman KF. Specific Absorbed Fractions of Energy at Various Ages from Internal Photon Sources. I. Methods. Oak Ridge, TN: Oak Ridge National Laboratory; 1987. ORNL/TM-8381/V8381.
8. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
9. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol. 2000;27:627-630.
10. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273-289.
11. Holmes CJ, Hoge R, Collins L, Woods R, Toga AW, Evans AC. Enhancement of MR images using registration for signal averaging. J Comput Assist Tomogr. 1998;22:324-333.
12. Papademetris X, Jackowski M, Rajeevan N, Constable RT, Staib LH. Bioimage suite: An integrated medical image analysis suite. Insight J. 2006;2006:209.
13. Gallezot JD, Nabulsi N, Holden D, et al. Development of a lysophosphatidic acid receptor 1 (LPA1) radioligand for lung imaging with PET [abstract]. J Nucl Med. 2014;55(suppl 1):96.
14. Frankle WG, Huang Y, Hwang DR, et al. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med. 2004;45:682-694.
15. Gallezot JD, Zheng MQ, Lim K, et al. Parametric imaging and test-retest variability of 11C-(1)-PHNO binding to D2/D3 dopamine receptors in humans on the high-resolution research tomograph pet scanner. J Nucl Med. 2014;55:960- 966.
16. Gomez L, Breitenbucher JG. PDE2 inhibition: potential for the treatment of cognitive disorders. Bioorg Med Chem Lett. 2013;23:6522-6527.
17. Morgan P, Van Der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today. 2012; 17:419-424.
18. Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014;13: 290-314.
19. Rombouts FJ, Tresadern G, Buijnsters P, et al. Pyrido[4, 3-e][1, 2, 4]triazolo[4, 3-A] pyrazines as selective, brain penetrant phosphodiesterase 2 (PDE2) inhibitors. ACS Med Chem Lett. 2015;6:282-286.